FDAnews Drug Daily Bulletin

Federal Judge Discards Amgen Complaint Against Genentech in Biosimilar Case

Feb. 8, 2018

A judge in California Central District Court denied a complaint filed by Amgen asking the court to invalidate 27 patents related to Genentech’s cancer treatment, Avastin.

The court also refused to transfer the case back to Delaware as Amgen requested, finding no basis for the request.

The two companies have been embroiled in patent disputes over Genentech’s blockbuster drug and Avastin’s biosimilar, Mvasi, and both have accused the other of violating or misinterpreting the Biologics Price Competition and Innovation Act.

View today's stories